Introduction
The involvement of endocannabinoid (eCB) system in the regulation of physio-pathological processes has generally accepted. Thus, the interest for potential therapeutic applications of cannabinoids is increasing. Among the pharmacological actions of cannabinoids, there are emerging evidence for a possible involvement of the eCB signalling in the control of mood and anxiety (Chhatwal and Ressler, 2007; Mangieri and Piomelli, 2007) . However, despite the fact that numerous studies have been focused on this issue, the anxiogenic/anxiolytic profile of action of cannabinomimetics has not been fully elucidated. For instance, some studies demonstrated that CB 1 receptor antagonists or genetic disruption of CB 1 receptors enhance anxiety in several paradigms in rodents (Kathuria et al. 2003; Haller et al., 2004) , thus suggesting the existence of an anxiolytic eCBs tone in the central nervous system (CNS). This hypothesis is supported by studies indicating that inhibitors of eCB reuptake or degradation display anxiolytic effects (Kathuria et al., 2003; Moreira et al., 2008; Micale et al., 2009 ). In addition, at selected doses, CB 1 receptor agonists reduce anxiety-related behavioural responses . Opposite results have been obtained in other studies. Degroot and Nomikos (2004) demonstrated that either genetic deletion or pharmacological blockade of CB 1 receptors reduces anxiety, whereas cannabinoid agonists displayed anxiogenic responses, generally at doses higher than those showed to be anxiolytic . Taken together, these results indicate that cannabinoids can both suppress and worsen anxiety-like behaviours depending on a set of variables such as the drug dose, genetic background, environmental context and the behavioural test used. Moreover, it cannot be excluded that the interaction with other neuronal systems such as GABA or cholecystokinin (CCK) by cannabinoids (Katona et al. 1999; Rotzinger and Vaccarino 2003; Ali 2007) may be state dependent which can contribute to these variable results.
Among the endogenous compounds supposed to have a crucial role in anxiety, CCK, a gut-brain peptides, has been postulated to be one of the most important (Rotzinger and Vaccarino 2003) . The sulphated carboxy-terminal octapeptide (CCK-8S) is the predominant active form of the peptide with a high brain distribution. CCK 2 receptor is the main CCK receptor subtype presents in the CNS, and its distribution is consistent with the functions attributed to neural CCK, including regulation of feeding, control of learning and memory, behavioural expression of anxiety and mediation of pain (Chandra and Liddle, 2007) . The presence of CCK receptors in brain regions assumed to control emotions such as the cerebral cortex and the limbic system, the responsiveness of cortical and amygdala endogenous CCK system to anxiety and other stressful stimuli, as well as CB 1 receptor high levels have been found on the terminals of CCK-positive GABAergic interneurons in several brain areas (Katona et al., 1999) . Hippocampal CB 1 receptor activation inhibits potassium-evoked CCK release (Beinfeld and Connolly, 2001 ) and eCBs can function as retrograde messengers, modulating CCK release (Valverde, 2005; Chhatwal et al., 2009 ). These findings raised the hypothesis for the existence of a reciprocal interaction between eCBs and CCK (Valverde, 2005; Kurrikoff et al., 2008; Chhatwal et al., 2009 ) which could represent the first step of a cascade of events which may regulate the functional activity of other neuronal systems related to anxiety processes, such as the GABAergic one. On this background, in this study the possible existence of a functional interaction between eCBs and CCK systems in controlling GABAergic neuronal transmission in the rat cerebral cortex, a brain region that is important in regulating a variety of emotion-related behaviour, has been evaluated. Thus, the effects of pharmacological treatments with CB 1 and CCK 2 receptors agonists/antagonists, as well as compounds that enhance eCB signalling by inhibiting degradation, e.g. the fatty acid amide hydrolase (FAAH) inhibitor URB597, or reuptake (UCM707), were studied both on spontaneous and electrically-evoked 
Methods

Animal care
All experiments were performed in accordance with the guidelines issued by the Italian Ministry of Health, the Declaration of Helsinki and the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institute of Health (USA).
Cortical cell cultures preparation
Primary cultures of cortical neurons were prepared from embryonic day 18 Sprague-Dawley rats.
Removed cortices were dissected free of meninges and dissociated in 0.025% (wt/vol) trypsin. The tissue fragments were dissociated mechanically by gentle pipetting through wide and narrow bore fire polished Pasteur pipettes in culture medium (Neurobasal medium with supplements of 0.1 mM glutamine, 10μg/ml gentamicine and 2% B27). The cells were counted and then plated on poly-Llysine (5μg/ml)-coated dishes at a density of 2.5 x 10 6 cells/dish. Cultures were grown at 37° C in a humidified atmosphere of 5% CO 2 /95% air. Cytosine arabinoside (1 μ M) was added at 5 days in vitro (DIV) to prevent glial cell proliferation. The cultures were maintained for 8 DIV before experiments.
Experimental protocol
Preloaded [
3 H]GABA was used as a tracer of endogenous GABA. Experiments were performed as previously described (Tomasini and Antonelli, 1998) . Before starting the release experiment, the dishes containing the cells were rinsed three times by replacing the culture medium with 1 ml of warmed (37°C) Krebs Ringer-bicarbonate buffer in mM: NaCl 118. Pharmacological treatments (see above) were carried out by adding the tested compound(s) to the perfusion medium 10 min before St 2 (Fig. 1B) . In the case of combined treatments both drugs were administered simultaneously.
The tritium distribution in the samples collected (basal condition and stimulation) and that retained in the cells at the end of the experiment (0.025 M NaOH extracts) was determined by liquid scintillation spectrometry.
Materials
The culture dishes were purchased from Nunc A/S (Roskilde,Denmark). Neurobasal medium and 
Data presentation and statistical analysis
The amount of tritium released per 5-min sample was calculated either as pmol/min or as fraction of the total tissue tritium content at the beginning of the respective collection period (fractional rate).
The effects of treatments on spontaneous [ mA/cm 2 , 2 msec, 2 min) in the first period of stimulation (St 1 ) was 0.14 pmol/2 min (n= 40) and remained quite similar during the second period of stimulation (St 2 ), the St 2 /St 1 ratio being close to unity (1.02 ± 0.042; n=40).
Results
Spontaneous
Effects of CCK-8S alone or in the presence of LY225910
CCK-8S (300 and 1000 nM) applied 10 min before St 2 , concentration-dependently increased the electrically-evoked [ LY225910 did not affect, on its own, the electrically-evoked tritium overflow.
Effects of WIN55,212-2 alone or in the presence of SR141716A
The addition to the superfusion medium of WIN55,212-2 (100-1000 nM), 10 min before 
Effects of URB597 alone or in the presence of SR141716A
As shown in Fig. 4A , the inhibitor of FAAH URB597 (10 nM), added to the superfusion medium 10 min before St 2 , induced a significant reduction of electrically-evoked [ 3 H]GABA overflow. On the contrary, the lower concentrations (0.1-1 nM) of URB597 were ineffective. The inhibition induced by URB597 (10 nM) was fully counteracted in the presence of SR141716A (100 nM; Fig.   4B ).
Effects of UCM707 alone or in the presence of SR141716A
The addition of the eCB reuptake inhibitor UCM707 (3 µM) to the perfusion medium, 10 min before St 2 , was associated with a significant reduction of the electrically-evoked 
Effects of WIN55,212-2 in combination with CCK-8S
In this set of experiment, the effect induced by the co-perfusion of WIN55,212-2 with CCK-8S on electrically-evoked [ 3 H]GABA overflow, was analysed. As illustrated in Fig. 6 , when WIN55,212-2 and CCK-8S were simultaneously added, at concentrations by themselves ineffective (1 nM and 3 nM, respectively), to the superfusion medium 10 min before St 2 , a significant enhancement of the St 2 /St 1 ratio was found. Interestingly, the increase in electrically-evoked [ 3 H]GABA overflow induced by the combination of WIN55,212-2 and CCK-8S was fully counteracted either by the CB 1 antagonist SR141716A (100 nM; Fig. 6 ) or by the CCK 2 receptor antagonist LY225910 (100 nM; Fig. 6 ). At the concentrations tested, the co-perfusion of WIN55,212-2 with CCK-8S did not affect
Effects of URB597 or UCM707 in combination with CCK-8S
In view of the above results, the effects of URB597 and UCM707, at concentrations by themselves ineffective, were tested in the presence of an ineffective concentration of CCK-8S. The coperfusion of URB597 (1 nM) with CCK-8S (3 nM) induced a significant enhancement of the electrically-evoked [ 3 H]-GABA efflux (Fig. 7) . In the presence of the CB 1 receptor antagonist SR141716A (100 nM; 
Discussion
In cerebral cortex cell cultures, about 45% of the total cell are GABAergic neurons (Tomasini and Antonelli, 1998 can be speculated that, by increasing GABA signaling, CCK can modulate the release of other neurotransmitter(s) also involved in the control of anxiety. Furthermore, since CCK 2 agonists reduced the postsynaptic membrane responsiveness to GABA (McLean et al., 1996) , it may be speculated that the increase in cortical GABA release by CCK 2 receptor activation might ensure the physiological feedback mechanism addressed to control the forebrain circuitry homeostasis.
Interestingly, like CCK 2 antagonists, anxiolytic drugs such as diazepam and buspirone also reduce cortical GABA transmission (Schacht and Bäcker, 1979; Siniscalchi et al., 2003) .
In contrast to CCK-8S, CB 1 receptor agonists like WIN55,212-2, reduce the electrically evoked findings, demonstrating that in the cerebral cortex of the awake rat, CB 1 receptor activation induced a decrease in dialysate GABA levels (Ferraro et al., 2001; Pistis et al., 2002) . The observed CB 1 receptor-mediated decrease in [ 3 H]GABA overflow is also in line with previous in vitro studies performed in other brain areas (Katona et al., 1999) .
This article has not been copyedited and formatted. The final version may differ from this version. receptors. The results with UCM707 are in contrast with previous reports (Melis et al., 2004; Ronesi et al., 2004; Adermark and Lovinger, 2007; Adermark et al., 2009 ) demonstrating that the eCB membrane transporter acts bidirectionally and it is necessary for the eCB release. Therefore, eCB uptake inhibitors have been suggested to prevent eCB release and block eCB-mediated effects.
At the present, this discrepancy remains to be clarify. However, while the bidirectionality of the eCB membrane transporter has been reported, based upon temperature-dependency and pharmacological inhibition of cellular anandamide release or effects (Hillard and Jarrahian, 2000) , other experiments aimed to characterize this feature of the transporter led to conflicting results. Kathuria et al. (2003) demonstrated that anandamide release is linear with time and unaffected by the putative transport inhibitor AM404, thus concluding that the eCB release is simple diffusion process. Thus, the exact mechanisms responsible for eCB efflux have not been clarified and it seems likely that several factors (biosynthesis, transmembrane eCB gradient, protein-mediated transport) could contribute to eCB levels (Glaser et al., 2005) . In view of this, it can be hypothesized that under the present experimental conditions, eCB efflux is quite independent from the eCB transporter, thus explaining the effect of UCM707. In line with this, several reports reported an increase of anandamide effects following the treatments with eCB transporter inhibitors (Ortega-Gutiérrez et al., 2005; de Lago et al., 2007; Hasanein and Javanmardi, 2008 There is an intriguing possibility for an interaction between the two receptors at the plasma membrane level. Thus, the existence also of a CB 1 -CCK 2 heteromer on the cortical GABAergic terminals besides monomers and homodimers of these receptors could be hypothesized. The postulated CB 1 -CCK 2 heteromer may possess a CB 1 receptor agonist binding site with an especially high affinity due to a conformational change in the heteromer (see Fuxe et al., 2008) leading to the development of a facilitatory CB 1 -CCK 2 receptor interaction in control of GABA release with low nanomolar concentrations of CB 1 agonists. Due to the inhibitory effects of CB 1 agonists on GABA release coming up with higher concentrations, this mechanism may be difficult to observe at such concentrations due to actions of the CB 1 agonist also at CB 1 monomers and homodimers. This hypothesis will now be tested in biochemical binding and signalling experiments on the CB 1 and CCK 2 receptors. It should be noted however that the PKC inhibitor blocked these facilitatory CB 1 -CCK 2 receptor interactions on GABA release indicating that the PKC activation by the CB 1 receptor through coupling to PLC (Arnould et al., 2004) In line with the very high coexpression of CB 1 and CCK peptides in cortical areas (Marsicano and Lutz, 1999) , several findings have suggested the existence of a possible functional cross-talk between the two transmitter systems. Marsicano and Lutz (1999) proposed that an increased stimulation by cannabinoids might lead to decreased levels of CCK, with a possible involvement of this event in some pathological conditions, such as schizophrenia. In accordance, in vitro studies demonstrated that the activation of CB 1 receptors in rat hippocampal slices inhibits potassiumevoked CCK release, thus suggesting that this mechanism could contribute to the spatial memory defects produced by cannabinoids (Beinfeld and Connolly, 2001) . Functional implications of the high rates of co-localization between eCBs and CCK, have also been reported by Fride (2005) . The present results suggest, for the first time, a functional interaction between eCBs and CCK in modulating cortical GABAergic transmission. In view of the in vitro model utilized, it is not possible to determine the importance of this interaction for the anxiolytic/anxiogenic effects of CB 1 agonists and for the anxiogenic effects of CCK 2 receptors and actually this remains just a speculation. However, it represents an attractive mechanism to be investigated in future behavioural experiments.
In conclusion, the present results discovered an inhibitory and excitatory role of CB 1 and CCK 2 receptors, respectively, in modulating electrically-evoked GABA overflow from cortical GABA neurons in vitro. The demonstrated novel facilitatory CB1/CCK 2 receptor interactions in the control of cortical GABA release opens up the possibility of the existence of a CB 1 -CCK 2 receptor heteromer on cortical GABA terminals. Its CB 1 receptor seems to possess an especially high affinity for agonists enhancing the PLC-mediated signalling over the participating CCK 2 receptor producing an increase in electrically evoked cortical GABA release.
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